Soon-Shiong P, Heintz R E, Merideth N, Yao Q X, Yao Z, Zheng T, Murphy M, Moloney M K, Schmehl M, Harris M
St Vincent Medical Center, Los Angeles, CA 90057.
Lancet. 1994 Apr 16;343(8903):950-1. doi: 10.1016/s0140-6736(94)90067-1.
Identification of a biocompatible immunoprotective membrane to prevent graft rejection remained elusive until the development of microcapsules formulated in alginate high in guluronic acid. We report insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Encapsulated human islets were injected intraperitoneally in a diabetic patient with a functioning kidney graft. Insulin independence with tight glycaemic control was demonstrated 9 months after the procedure. These results warrant a trial of a high dose of encapsulated islets in early-onset diabetic patients.
在开发出由高古洛糖醛酸海藻酸盐制成的微胶囊之前，寻找一种能防止移植排斥的生物相容性免疫保护膜一直没有结果。我们报告了一例1型糖尿病患者在胰岛移植后实现了胰岛素非依赖。将封装的人胰岛经腹腔注射到一名有功能肾移植的糖尿病患者体内。术后9个月实现了胰岛素非依赖且血糖得到严格控制。这些结果为在早发型糖尿病患者中进行高剂量封装胰岛的试验提供了依据。
